Top Page
Recce Pharmaceuticals Ltd.
(Sydney:RCE)
Recce Pharmaceuticals Ltd. (RCE) vs. iShares MSCI Australia ETF (EWA)
Recce Pharmaceuticals Ltd. Business Overview & Revenue Model
Recce Pharmaceuticals Ltd. Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 6.95M | 6.85M | 4.37M | 3.08M | 1.64M | 1.12M | Gross Profit |
| -1.62M | -366.77K | 4.15M | 2.90M | 1.34M | 920.91K | EBIT |
| -26.90M | -22.05M | -17.33M | -14.15M | -15.36M | -5.41M | EBITDA |
| -19.12M | -21.35M | -16.99M | -10.80M | -14.77M | -5.13M | Net Income Common Stockholders |
| -17.94M | -17.66M | -13.08M | -10.99M | -13.51M | -4.32M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 1.94M | 4.42M | 1.56M | 11.58M | 20.87M | 2.68M | Total Assets |
| 4.21M | 6.37M | 2.56M | 12.62M | 21.68M | 3.24M | Total Debt |
| 4.74M | 811.19K | 250.57K | 74.76K | 126.95K | 83.23K | Net Debt |
| 2.80M | -3.60M | -1.31M | -11.51M | -20.75M | -2.60M | Total Liabilities |
| 9.19M | 15.89M | 5.14M | 2.56M | 1.18M | 931.53K | Stockholders Equity |
| -4.99M | -9.52M | -2.59M | 10.06M | 20.50M | 2.31M |
| Cash Flow | Free Cash Flow | ||||
| -13.47M | -13.15M | -12.73M | -9.05M | -7.93M | -3.81M | Operating Cash Flow |
| -13.42M | -13.01M | -12.69M | -9.01M | -7.86M | -3.81M | Investing Cash Flow |
| -409.57K | -141.90K | -38.63K | -40.34K | -76.01K | -5.94K | Financing Cash Flow |
| 11.76M | 16.00M | 2.71M | -240.50K | 26.12M | 6.09M |
Recce Pharmaceuticals Ltd. Technical Analysis
Recce Pharmaceuticals Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$38.66M | ― | -36.95% | ― | ― | 11.11% | |
54 Neutral | $5.31B | 3.29 | -45.39% | 2.79% | 16.77% | -0.07% | |
53 Neutral | AU$699.91M | ― | -112.97% | ― | ― | -84.82% | |
43 Neutral | AU$83.84M | ― | ― | ― | -33.01% | ||
40 Underperform | AU$89.97M | ― | -85.35% | ― | 315.11% | 51.16% | |
36 Underperform | AU$3.32M | ― | -119.28% | ― | ― | 64.10% |
Recce Pharmaceuticals Ltd. Corporate Events
Recce Pharmaceuticals Ltd has successfully completed a capital raising of A$15.8 million, including a shortfall placement of approximately 26.4 million shares to existing institutional and sophisticated investors, raising A$7.4 million. The funds will support significant Phase 3 clinical trials for topical treatments in Indonesia and Australia, aiming for commercialization and an Investigational New Drug Application to the US FDA. This capital raising marks a crucial step for Recce as it progresses towards establishing a new standard of care in infectious diseases, potentially improving patient outcomes and enhancing the company’s market position.
Recce Pharmaceuticals Ltd. has received a Notice of Acceptance from the China National Intellectual Property Administration for its patent on anti-infectives, extending its patent portfolio to the world’s second-largest pharmaceutical market. This development is significant as it validates Recce’s innovative treatments for various infections and enhances its market positioning, potentially benefiting stakeholders by tapping into a growing Chinese antibiotic market projected to expand at a CAGR of 5.7% from 2025 to 2030.
FIL Limited has increased its stake in Recce Pharmaceuticals Ltd., now holding 16,755,072 shares, which represents a 6.40% voting power in the company. This change in substantial holding reflects FIL Limited’s continued investment in Recce Pharmaceuticals, potentially signaling confidence in the company’s strategic direction and its innovative approach to tackling antibiotic resistance, which could have significant implications for stakeholders and the broader pharmaceutical industry.
Recce Pharmaceuticals Ltd announced a change in the director’s interest, with Dr. John Prendergast acquiring 51,136 fully paid ordinary shares through participation in the company’s pro-rata non-renounceable entitlement offer. This acquisition reflects an increase in Dr. Prendergast’s holdings, potentially signaling confidence in the company’s strategic direction and financial health, which may positively influence stakeholder perception and market positioning.
Recce Pharmaceuticals Ltd. successfully completed an entitlement offer, raising approximately A$3.4 million from existing shareholders, contributing to a total of A$8.4 million raised including a previous placement. This funding will support Phase 3 clinical trials for Diabetic Foot Infection in Indonesia and Acute Bacterial Skin and Skin Structure Infections in Australia, with an aim for commercialization and revenue generation by 2026. The company expressed gratitude towards its shareholders for their support and highlighted the importance of these trials as a catalyst for future revenue.
Recce Pharmaceuticals Ltd has announced the quotation of 12,273,033 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of May 16, 2025. This move is part of previously announced transactions and is expected to enhance the company’s financial position, potentially impacting its market presence and stakeholder interests positively.
Recce Pharmaceuticals Ltd announced the receipt of a US$175,122 rebate from the Canadian Government under the SR&ED Tax Incentive program, which supports R&D activities in Canada. This rebate complements the Australian government’s R&D Tax Incentive, highlighting Recce’s expanding research efforts and the international support for their innovative anti-infective developments.
Recce Pharmaceuticals Ltd has announced an update to its previous announcement regarding the proposed issue of securities. The company has revised the dates for the offer closing, trading commencement on a deferred settlement basis, and the issue date, among others. This update is crucial for stakeholders as it outlines the timeline for the securities offering, which could impact the company’s financial strategy and market positioning.
Recce Pharmaceuticals Ltd has announced an extension of the closing date for its pro-rata non-renounceable entitlement offer, allowing eligible shareholders more time to participate. The offer aims to raise up to $10.8 million and provides an opportunity for shareholders to apply for additional shares under the shortfall offer, potentially impacting the company’s financial position and market operations.
Recce Pharmaceuticals has entered into a Cooperative Research and Development Agreement with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), supported by the Defense Threat Reduction Agency. This agreement will involve testing Recce’s synthetic anti-infective, RECCE 327, against biodefense pathogens in USAMRIID’s high biocontainment facilities. This partnership complements a recent US$2 million grant from the U.S. Department of Defense for a burn wound program, enhancing Recce’s collaboration with U.S. Government initiatives and potentially advancing the development of R327 as a treatment for severe infections.
Recce Pharmaceuticals Ltd announced the availability of a recording from their recent investor webinar, where company executives discussed updates on clinical activities and the outlook for upcoming Phase 3 trials. They also detailed a recent AUD ~$15.8 million Placement and Entitlement Offer, which will support their clinical activities as they move towards commercialization in 2026.
Recce Pharmaceuticals Ltd has announced a pro-rata non-renounceable entitlement offer to raise approximately $10.8 million, aimed at funding Phase III clinical trials and other development programs. The offer is available to eligible shareholders in specific regions, while ineligible shareholders have been notified of their exclusion due to cost and regulatory considerations. The funds will support trials in Indonesia and Australia, as well as additional clinical activities and working capital, positioning the company for potential revenue generation in 2026.
Recce Pharmaceuticals Ltd. has announced the opening of a pro-rata non-renounceable entitlement offer, allowing eligible shareholders to purchase one new share for every six shares held at an issue price of $0.28 per share. This offer aims to raise approximately $10.8 million before costs, with the funds potentially enhancing the company’s operational capabilities and market position.
Recce Pharmaceuticals Ltd. has received Human Research Ethics Committee approval to expand its Phase II clinical trial for the RECCE® 327 Topical Gel, allowing up to 20 additional diabetic patients with foot infections to participate. This decision follows promising Phase II results, where the gel showed high efficacy in treating acute bacterial skin and skin-structure infections, including diabetic foot ulcer infections. The study aims to address the urgent need for effective treatments, as diabetic foot infections have high recurrence rates and can lead to severe complications. The trial will run alongside Recce’s Phase 3 programs in Indonesia and Australia, further supporting the company’s clinical momentum and data portfolio.
Recce Pharmaceuticals Ltd. has announced the issuance of 17,857,143 fully paid ordinary shares, raising A$5.0 million as part of a recent placement. This move is aligned with the company’s ongoing efforts to fund additional clinical trials, for which they are in the process of obtaining necessary approvals, potentially enhancing their position in the pharmaceutical industry by advancing their anti-infective product pipeline.
Recce Pharmaceuticals Ltd has successfully completed a A$5.0 million placement of new shares to support Phase 3 clinical trials for diabetic foot infection in Indonesia and acute bacterial skin infections in Australia. Additionally, the company is launching a pro-rata entitlement offer to raise up to A$10.8 million, further bolstering its financial resources for ongoing clinical developments. These financial maneuvers are expected to strengthen Recce’s position in the pharmaceutical industry, particularly in addressing unmet medical needs related to antibiotic resistance.
Recce Pharmaceuticals Ltd has announced the quotation of 17,857,143 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code RCE. This move is part of previously announced transactions and may enhance the company’s financial flexibility and market presence, potentially impacting its operational capabilities and stakeholder interests positively.
Recce Pharmaceuticals Ltd. announced an upcoming investor webinar where key executives will discuss recent clinical activities, the outlook for Phase 3 clinical trials, and details of a recent AUD ~$15.8 million Placement and Entitlement Offer. This funding is pivotal for supporting Recce’s clinical activities as it progresses towards commercialization in 2026, potentially strengthening its position in the pharmaceutical industry and offering significant implications for stakeholders.
Recce Pharmaceuticals Limited announced an equity raising initiative through a placement and entitlement offer of new fully paid ordinary shares. This move is aimed at bolstering the company’s financial resources to further its development and commercialization efforts. The offer is restricted to certain jurisdictions, emphasizing compliance with applicable securities laws, and is not available to investors in the United States.
Recce Pharmaceuticals Ltd. announced a $5 million placement to an Australian private investor and a pro-rata non-renounceable entitlement offer to raise approximately $10.8 million. The capital raising initiatives are expected to affect shareholder control dynamics, with potential dilution for existing shareholders due to the placement and entitlement offer.
Recce Pharmaceuticals Ltd has announced a capital raising initiative totaling approximately A$15.8 million, consisting of a A$5.0 million placement from an Australian-based private investor and a A$10.8 million entitlement offer to shareholders. The funds will support Phase III clinical trials for diabetic foot infections in Indonesia and acute bacterial skin and skin structure infections in Australia, with the potential to generate revenue by 2026. This capital raise is seen as a pivotal step for Recce, potentially enhancing its market position and offering significant value to shareholders as it progresses with its clinical trials.
Recce Pharmaceuticals Ltd announced a proposed issue of securities, with a total of 38,645,269 ordinary fully paid securities to be issued through a standard pro rata issue and an additional 17,857,143 securities through a placement. This move is likely aimed at raising capital to support the company’s operations and strategic initiatives, potentially enhancing its market position and providing opportunities for stakeholders.
Recce Pharmaceuticals Ltd has released a corporate presentation detailing its focus on developing and commercializing synthetic anti-infectives. The presentation outlines the company’s strategic intentions and future plans, although it emphasizes that these are subject to various risks and uncertainties. The company disclaims any responsibility for the accuracy or completeness of the information provided, and it does not constitute an offer to sell or buy securities.